Univest
Univest
  • Markets

Aarey Drugs & Pharmaceuticals Ltd. Hits Upper Circuit on BSE, 1 October 2026

  • October 1, 2026
  • Posted by: Kunal Singla
  • Category: News
No Comments
Aarey Drugs & Pharmaceuticals Ltd. Hits Upper Circuit on BSE, 1 October 2026

On 1 October 2026, Aarey Drugs & Pharmaceuticals Ltd. (AAREYDRUGS) hit the upper circuit on BSE at Rs 107.55, a 4.96% positive move from the previous close of Rs 102.47. The company’s market cap stood at Rs 316.37 crore. The upper circuit price for the session was Rs 107.55.

The move was driven by buying interest against the exchange-defined price band. At the time of writing the stock was locked at its upper circuit level, which makes the session worth noting for short-term market participants.

Table of Contents

Toggle
  • Key Takeaways
  • Key Market Data
  • Price Action and Trading Activity
  • Why Aarey Drugs & Pharmaceuticals Ltd. Hit Upper Circuit
  • What the Upper Circuit Means
  • Aarey Drugs & Pharmaceuticals Ltd. Fundamentals and Valuation
  • Peer and Sector Context
  • Technical Snapshot
  • What Readers Should Know
  • Frequently Asked Questions
    • Why did Aarey Drugs & Pharmaceuticals Ltd. hit upper circuit on 1 October 2026?
    • What was AAREYDRUGS share price on 1 October 2026?
    • What was the upper circuit price for AAREYDRUGS?
    • What is Aarey Drugs & Pharmaceuticals Ltd.’s market cap and PE ratio?
    • Which exchange and data source were used?
    • Does hitting an upper circuit mean Aarey Drugs & Pharmaceuticals Ltd. is a buy or a sell?
    • Can you buy or sell Aarey Drugs & Pharmaceuticals Ltd. shares when the stock is at the upper circuit?
    • What happens the next trading session after an upper circuit?
    • What is the upper circuit limit set at for Indian stocks?

Key Takeaways

  • Aarey Drugs & Pharmaceuticals Ltd. (AAREYDRUGS) hit the upper circuit on BSE at Rs 107.55 on 1 October 2026.
  • The session move was +4.96% against a previous close of Rs 102.47.
  • Market capitalisation stood at Rs 316.37 crore with a PE ratio of 75.76.
  • No official company announcement or verified catalyst was confirmed at the time of writing.
  • A price band is an exchange trading rule, not a view on the company or a recommendation.

Key Market Data

Metric Value
Stock Aarey Drugs & Pharmaceuticals Ltd.
Current Price / LTP Rs 107.55
Day Move 4.96%
Previous Close Rs 102.47
Day Open Rs 105.75
Day High Rs 107.55
Day Low Rs 104.15
Upper Circuit Price Rs 107.55
Upper Circuit Limit Rs 107.55
Market Cap Rs 316.37 crore
Selected Exchange BSE
PE Ratio 75.76

All figures above are as of 1 October 2026, sourced from Univest market data for the BSE listing. Only fields present in the source for this session are shown.

Price Action and Trading Activity

Aarey Drugs & Pharmaceuticals Ltd. opened at Rs 105.75 on BSE, compared with a previous close of Rs 102.47. During the session, the stock traded between Rs 104.15 and Rs 107.55 before touching the upper circuit price of Rs 107.55.

The absolute day change was Rs 5.08, while the percentage move was 4.96%. The event figures are kept to a single exchange so the numbers stay comparable.

The selected exchange matters because price bands, day range and previous-close values can differ across exchanges. This article uses BSE consistently for the event table and narrative. The stated upper circuit limit for the session was Rs 107.55, which is the level the price reached.

Why Aarey Drugs & Pharmaceuticals Ltd. Hit Upper Circuit

Aarey Drugs & Pharmaceuticals Ltd. hit the upper circuit after buying interest pushed the stock to its exchange-defined price band. No official company announcement or verified external catalyst was confirmed at the time of writing, so the move should be read primarily through price action and market sentiment.

Because no verified catalyst was available, this article does not attribute the move to earnings, corporate action, sector news, or market rumours. If a confirmed announcement becomes available later, it should be added as a separate update.

Within the session the stock reached the upper circuit level of Rs 107.55.

What the Upper Circuit Means

An upper circuit is the maximum price level a stock is allowed to reach during a trading session under the applicable exchange price band. For Aarey Drugs & Pharmaceuticals Ltd., the captured upper circuit price was Rs 107.55 on 1 October 2026.

The circuit mechanism is meant to slow extreme price movement and keep trading orderly. It is a market-structure fact, not a return forecast. In this article, the upper circuit explains what happened in the session and where the price band was reached.

Aarey Drugs & Pharmaceuticals Ltd. Fundamentals and Valuation

Available market data gives a fuller picture than price action alone. For Aarey Drugs & Pharmaceuticals Ltd., PE ratio was 75.76, PB ratio was 1.93, book value was Rs 53.01, EPS was 1.35, ROE was 3.02%, ROCE was 6.38%, dividend yield was 0% and debt-to-assets ratio was 0.26, on a market cap of Rs 316.37 crore. These are available financial indicators and should not be read as a buy, sell, or hold view.

At the reported PB ratio of 1.93, the market valued Aarey Drugs & Pharmaceuticals Ltd. above its reported book value per share. That premium can reflect growth expectations, asset quality, or simply thin trading in a smaller counter.

For investors tracking upper circuit moves, these metrics help separate the price event from the broader financial profile. A sharp one-day move can attract attention, but valuation and return ratios still need to be reviewed separately.

Peer and Sector Context

Aarey Drugs & Pharmaceuticals Ltd. belongs to the Trading industry. The peer table below uses available companies from the same sector or industry to give broader valuation context.

Peer Company Market Cap PE PB ROE
Confidence Petroleum India Ltd. Rs 2931.03 crore 21.77 1.99 7%
Vintage Coffee & Beverages Ltd. Rs 2626.54 crore 33.35 4.67 17.91%
Fischer Medical Ventures Ltd. Rs 2340.6 crore 78.48 5.03 9.38%
Aayush Art And Bullion Ltd. Rs 1976.27 crore 250.42 32.52 13.89%
Khazanchi Jewellers Ltd. Rs 1771.26 crore 17.35 5.1 32.45%

Several of these peers are far larger by market capitalisation than Aarey Drugs & Pharmaceuticals Ltd. Size differences change liquidity and cost of capital, so the table is sector context rather than a like-for-like ranking.

Aarey Drugs & Pharmaceuticals Ltd.’s PE ratio was 75.76, compared with an available peer PE average of 80.27, calculated from the 5 peer companies that had a PE on record. This comparison is a valuation reference point, not a recommendation.

Want to know more? Log in to Univest for more stock insights.

Technical Snapshot

The technical snapshot adds context: RSI was 65.48, the 50-day moving average was 96.49 and the 200-day moving average was 83.21.

What Readers Should Know

The main confirmed fact is that Aarey Drugs & Pharmaceuticals Ltd. hit the upper circuit on BSE at Rs 107.55 on 1 October 2026, with a 4.96% day move.

The practical limitation after an upper-circuit session is execution. Buyers queue at the band and sellers step back, so the quoted price is not necessarily a price you can transact at. The other limitation is that no official catalyst was confirmed at the time of writing.

Readers should treat upper circuit events as market updates, not standalone investment conclusions. The price band shows strong near-term interest, but follow-up analysis should consider business fundamentals, valuation, liquidity, risk, and confirmed company disclosures.

Frequently Asked Questions

Why did Aarey Drugs & Pharmaceuticals Ltd. hit upper circuit on 1 October 2026?

The stock reached its upper price band after buying interest during the session. No official company announcement or verified external catalyst was confirmed at the time of writing.

What was AAREYDRUGS share price on 1 October 2026?

The last traded price used in this article was Rs 107.55 on BSE. That price matched the upper circuit price captured for the event.

What was the upper circuit price for AAREYDRUGS?

The upper circuit price was Rs 107.55. The stated exchange upper circuit limit was Rs 107.55. The event numbers in this article are aligned to BSE.

What is Aarey Drugs & Pharmaceuticals Ltd.’s market cap and PE ratio?

Aarey Drugs & Pharmaceuticals Ltd.’s market cap was Rs 316.37 crore. PE ratio was 75.76.

Which exchange and data source were used?

The selected exchange was BSE. The article uses Univest market data available at the time of generation, captured on 1 October 2026.

Does hitting an upper circuit mean Aarey Drugs & Pharmaceuticals Ltd. is a buy or a sell?

No. A circuit is an exchange price-band rule that caps how far a stock can move in a single session. It carries no view on valuation or business quality and is not a recommendation. Any decision should rest on fundamentals, valuation, liquidity and your own risk tolerance.

Can you buy or sell Aarey Drugs & Pharmaceuticals Ltd. shares when the stock is at the upper circuit?

It is usually difficult. At the upper circuit, buy orders queue up while sellers step back, so there may be no counterparty at the quoted price. Orders can stay unfilled until the band opens up or sellers return.

What happens the next trading session after an upper circuit?

There is no fixed outcome. The band resets each session, so the stock can open freely, hit the same band again, or reverse. The exchange can also revise the applicable band width. The useful signals to watch are whether the company files any disclosure explaining the move.

What is the upper circuit limit set at for Indian stocks?

Exchange price bands are commonly set at 2%, 5%, 10% or 20% depending on the security, and the applicable band can be revised by the exchange. For Aarey Drugs & Pharmaceuticals Ltd. the stated limit was Rs 107.55. For this session, Aarey Drugs & Pharmaceuticals Ltd. moved 4.96%.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Registration Number INH000013776), a subsidiary of Univest Communication Technologies Private Limited.



Author: Kunal Singla
Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.

Leave a Reply Cancel reply